Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89,600,000
-
Total 13F shares
-
61,735,739
-
Share change
-
-1,401,408
-
Total reported value
-
$1,157,500,538
-
Put/Call ratio
-
125%
-
Price per share
-
$18.75
-
Number of holders
-
115
-
Value change
-
-$20,078,116
-
Number of buys
-
60
-
Number of sells
-
55
Institutional Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q2 2023
As of 30 Jun 2023 Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) had 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 61,735,739 shares of stock of the company.
Largest 10 holders included Alphabet Inc., FMR LLC, ARK Investment Management LLC, VANGUARD GROUP INC, BlackRock Inc., STATE STREET CORP, FEDERATED HERMES, INC., Casdin Capital, LLC, Sumitomo Mitsui Trust Holdings, Inc., and Nikko Asset Management Americas, Inc..
This table shows 116 institutional shareholders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.